Immunopathogenesis of scleroderma - Evolving concepts

Mount Sinai Journal of Medicine

Volumn 68, Issue 4-5, 2001, Pages 233-242

  Sapadin, Allen N ^a   Esser, Adam C ^a   Fleischmajer, Raul ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion molecules; Cytokines; Scleroderma; Systemic sclerosis

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE;

ANTIBODY PRODUCTION; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC SCLEROSIS;

ANTIBODY FORMATION; CELL ADHESION MOLECULES; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; SCLERODERMA, SYSTEMIC;

EID: 0035464180     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Kinder R, Fleischmajer R. Systemic scleroderma: A review of organ systems. Int J Dermatol 1974; 13:382-395.
2. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Sci-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979; 254:10514-10522.
3. G-dimethylarginine). J Biol Chem 1985; 260:14304-14310.
4. Fleischmajer R, Perlish JS, Duncan M. Scleroderma: A model for fibrosis. Arch Dermatol 1983; 119:957-962.
5. Wahl SM, Wahl LM, McCarthy JB. Lymphocyte-mediated activation of fibroblast proliferation and collagen production. J Immunol 1978; 121:942-946.
6. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). Am J Med 1969; 46:428-440.
7. Cannon PJ, Hassar M, Case DB, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974; 53:1-46.
8. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by wide field capillaroscopy. Arthritis Rheum 1973; 16:619-628.
9. Fleischmajer R, Dessau W, Timpl R, et al. Immunofluorescence analysis of collagen, fibronectin, and basement membrane protein in scleroderma skin. J Invest Dermatol 1980; 75:270-274.
10. Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ. Skin capillary changes in early systemic scleroderma. Arch Dermatol 1976; 112:1553-1557.
11. Fleischmajer R, Perlish JS. Capillary alterations in scleroderma. Arch Dermatol 1980; 113:161-171.
12. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma: The myth of the "uninvolved" skin. Arthritis Rheum 1991; 34:1495-1501.
13. Hebbar M, Gillot J-M, Hachulla E, et al. Early expression of E-selectin, tumor necrosis factor a, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996; 39:1161-1165.
14. Fleischmajer R, Perlish JS, Reeves JRT. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20:975-984.
15. Medsger TA, Jr, Rodnan GP, Moossy Y. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968; 11:554-568.
16. Hoskins LC, Norris HT, Gottlieb LS, Zamcheck N. Functional and morphologic alterations of the gastrointestinal tract in progressive systemic sclerosis (scleroderma). Am J Med 1962; 33:459-464.
17. Greenberger NJ, Dobrins WO, Ruppert RD, Jessep JE. Intestinal atony in progressive systemic sclerosis (scleroderma). Am J Med 1968; 45:301-308.
18. Murray-Lyon IM, Thompson RPH, Ansell ID, Williams R. Scleroderma and primary biliary cirrhosis. Br Med J 1970; 3:258-259.
19. Fleischmajer R, Perlish JS, West MS. Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 1977; 113:1661-1666.
20. Roumm AD, Whiteside TL, Medsger TA, Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthritis Rheum 1984; 27:645-653.
21. Prescott RJ, Freemont PW, Jones CJ. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166:255-263.
22. Yurowsky VV, Wigley FM, Wise RA, et al. Skewing of the CD8+ T cell repertoire in the lungs of systemic sclerosis patients. Hum Immunol 1996; 48:84-97.
23. LeRoy EC. Pathogenesis of scleroderma (systemic sclerosis). J Invest Dermatol 1982; 79(Suppl 1):87-89.
24. Fleischmajer R, Gay S, Perlish JS, Cesarini JP. Immunoelectron microscopy of Type III collagen in scleroderma skin. J Invest Dermatol 1980; 75:189-191.
25. Fleischmajer R, Gay S, Meigel WN, Perlish JS. Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 1978; 21:418-428.
26. Keene DR, Sakai LY, Bachinger HP, Burgeson RE. Type III collagen is present on banded collagen fibrils regardless of fibril diameter. J Cell Biol 1987; 105:2393-2402.
27. Fleischmajer R, Perlish JS, Burgeson RE, et al. Type I and type III collagen interactions during fibrillogenesis. Ann N Y Acad Sci 1990; 580:161-175.
28. Fleischmajer R, Darniano V, Nedwich, A. Scleroderma and the subcutaneous tissue. Science 1971; 171:1019-1021.
29. Perlish JS, Lenilich G, Fleischmajer R. Identification of collagen fibrils in scleroderma skin. J Invest Dermatol 1988; 90:48-54.
30. Krieg T, Langer J, Gerstmeier H, et al. Type III collagen amino-propeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 1986; 87:788-791.
31. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts "in vitro." J Clin Invest 1974; 54:880-889.
32. Buckinghan RB, Prince RK, Rodnan GP, Taylor F. Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J Lab Clin Med 1978; 92:5-21.
33. Fleischmajer R, Perlish JS, Krieg T, Timpl R. Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol 1981; 76:400-403.
34. Scharffetter K, Lanat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18:9-17.
35. Vuorio T, Maekela JK, Vuorio E. Activation of type I collagen genes in cultured scleroderma fibroblasts. J Cell Biochem 1985; 28:105-113.
36. Brady AH. Collagenase in scleroderma. J Clin Invest 1975; 56:1175-1180.
37. Fritzler KJ, Kinsella TD, Garbutte E. The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 1976; 69:520-526.
38. Moroi Y, Peebles C, Fritzler MJ, et al. Autoantibody to centromere (Kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 1980; 77:1672-1731.
39. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22:709-735.
40. Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest 1977; 59:176-178.
41. Reichlin M, Maddison PJ, Targoff I, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984; 4:40-44.
42. Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-ScI: Clinical and immunogenetic associations. Arthritis Rheum 1992; 35:1211-1217.
43. Muryoi T, Kasturi KN, Kafina MJ, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992; 175:1103-1109.
44. Reimer G, Rose KM, Scheer U, et al. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987; 79:65-72.
45. Gold HA, Topper JN, Clayton DA, et al. The RNA processing enzyme RNase MRP is identical to the Th RNP and related to RNase P. Science 1989; 245:1377-1380.
46. Gold HA, Craft J, Hardin JA, et al. Antibodies in human serum that precipitate ribonuclease P. Proc Natl Acad Sci U S A 1988; 85:5483-5487.
47. Okano Y, Medsger TA, Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990; 33:1822-1828.
48. Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37:75-83.
49. Boros P, Chen J, Bona C, Unkeless JC. Autoimmune mice make anti-Fcγ receptor antibodies. J Exp Med 1990; 171:1581-1595.
50. Davis K, Boros P, Keltz M, Unkeless JC, et al. Circulating Fc-γ receptor-specific autoantibodies in localized and systemic scleroderma. J Am Acad Dermatol 1995; 33:612-616.
51. Postlethwaite AE. Early immune events in scleroderma. Rheum Dis Arch N Am 1990; 16:125-139.
52. Gruschwitz M, Von Den Driesch P, Kellner P, et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992; 27:169-177.
53. Gruschwitz MS, Hornstein OP, Von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38:184-189.
54. Needleman BW. Increased expression of intercellular adhesion molecule-1 on the fibroblasts of scleroderma patients. Arthritis Rheum 1990; 33:1847-1851.
55. Shi-Wen X, Panesar M, Vancheeswaran R, et al. Expression and shedding of intercellular adhesion molecule-1 and lymphocyte function associated antigen-3 by normal and scleroderma fibroblasts. Effects of interferon-γ, tumor necrosis factor-α and estrogen. Arthritis Rheum 1994; 37:1689-1697.
56. Abraham D, Lupoli S, McWhirter A, et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991; 34:1164-1172.
57. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis - their role in early and late disease. Pathobiology 1993; 61:239-246.
58. Roberts A, Sporn M, Assovian RK, et al. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83:4167-4171.
59. Ignotz R, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986; 261:4337-4345.
60. Varga J, Rosenbloom J, Jimenez S. Transforming growth factor beta causes a persistent increase in steady state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 247:597-604.
61. Kikuchi K, Kadono T, Furue M, et al. Tissue inhibitor of metalloproteinase 1 (TIMP1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108:281-284.
62. Kikuchi K, Kubo M, Sato S, et al. Serum tissue inhibitor of metalloproteinase in patients with systemic sclerosis. J Am Acad Dermatol 1995; 33:973-979.
63. Yamakage A, Kikuchi K, Smith EA, et al. Selective upregulation of PDGF_ receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175:1227-1234.
64. Gruschwitz M, Muller PU, Sepp N, et al. Transcription and expression of transforming growth factor beta in the skin of progressive systemic sclerosis: A mediator of fibrosis? J Invest Dermatol 1990; 94:197-203.
65. Sfikakis PP, McCune B, Tsokos M, et al. Immunohistological demonstration of transforming growth factor beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993; 69:199-204.
66. Needleman BW, Choi J, Burrows-Mezu A, et al. Secretion and binding of transforming growth factor-beta by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990; 33:650-656.
67. Clark RA, Nielson LD, McPherson JM. Collagen matrices depress unstimulated and TGFβ stimulated fibroblast synthesis of collagen [abstract]. J Cell Biol 1987; 105:212A-218A.
68. Cotton SA, Jayson MTV, Hoyland J, et al. Altered vascular response in systemic sclerosis skin [abstract]. Br J Rheumatol 1997; 36(Suppl 1):30(53A)-33.
69. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999; 117:159-165.
70. Assoian RK, Fleurdelys BE, Stevenson HC, et al. Expression and secretion of type β transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987; 84:6020-6024.
71. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271:17779-17784.
72. Kahaleh MB, Yin T. The molecular mechanism of endothelial cell injury in scleroderma: Identification of granzyme 1 (a product of cytolytic T cell) in SSc. Arthritis Rheum 1990; 33:S67-S70.
73. Artlett CM, Smith B, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338:1186-1191.